Associations between central nervous system tumor diagnosis stage and survival and Medicaid enrollment among children, adolescents, and young adults.

IF 2.5 Q2 CLINICAL NEUROLOGY
Neuro-oncology practice Pub Date : 2024-10-03 eCollection Date: 2025-04-01 DOI:10.1093/nop/npae094
Kimberly J Johnson, Derek S Brown, Tess Thompson, Justin M Barnes, Allison A King
{"title":"Associations between central nervous system tumor diagnosis stage and survival and Medicaid enrollment among children, adolescents, and young adults.","authors":"Kimberly J Johnson, Derek S Brown, Tess Thompson, Justin M Barnes, Allison A King","doi":"10.1093/nop/npae094","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Medicaid enrollment has been associated with disparities in younger cancer patient survival. To further understand this association for central nervous system (CNS) tumor patients, we used Surveillance, Epidemiology, and End Results (SEER)-Medicaid-linked data to examine associations between Medicaid enrollment and enrollment timing and (1) diagnosis stage, and (2) CNS tumor death.</p><p><strong>Methods: </strong>Individuals diagnosed with a first malignant primary CNS tumor between 0 and 39 years from 2006 to 2013 were included. Medicaid enrollment was first classified as enrolled versus not enrolled with those enrolled further classified as having continuous, discontinuous (at diagnosis or other discontinuous), or other enrollment. We used logistic and Cox Proportional Hazards regression stratified by age to calculate adjusted odds ratios (ORs) and hazard ratios (HRs) for those 0-14 and 15-39 years.</p><p><strong>Results: </strong>Among 10 107 CNS tumor patients, we found significantly higher odds of regional/distant versus in situ/localized stage diagnoses for those with other discontinuous (OR<sub>0-14</sub> = 1.50, 95% CI: 1.15-1.95) and at diagnosis (OR<sub>15-39</sub> = 1.41, 95% CI: 1.11-1.78) Medicaid enrollment versus those not enrolled. Those enrolled versus not enrolled in Medicaid had a higher hazard of CNS tumor death for both age groups (HR<sub>0-14</sub> = 1.60 95% CI: 1.37-1.86; HR<sub>15-39</sub> = 1.50, 95% CI: 1.39-1.62) with the highest hazards for those enrolled at diagnosis (HR<sub>0-14</sub> = 1.83, 95% CI: 1.51-2.22; HR<sub>15-39</sub> = 1.93, 95% CI: 1.77-2.10).</p><p><strong>Conclusions: </strong>Medicaid enrollment is associated with a higher risk of CNS tumor death with an almost 2-fold higher risk for young CNS tumor patients enrolled at diagnosis. These results support the critical need for consistent health insurance coverage for young CNS tumor patients.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 2","pages":"246-256"},"PeriodicalIF":2.5000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913644/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nop/npae094","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Medicaid enrollment has been associated with disparities in younger cancer patient survival. To further understand this association for central nervous system (CNS) tumor patients, we used Surveillance, Epidemiology, and End Results (SEER)-Medicaid-linked data to examine associations between Medicaid enrollment and enrollment timing and (1) diagnosis stage, and (2) CNS tumor death.

Methods: Individuals diagnosed with a first malignant primary CNS tumor between 0 and 39 years from 2006 to 2013 were included. Medicaid enrollment was first classified as enrolled versus not enrolled with those enrolled further classified as having continuous, discontinuous (at diagnosis or other discontinuous), or other enrollment. We used logistic and Cox Proportional Hazards regression stratified by age to calculate adjusted odds ratios (ORs) and hazard ratios (HRs) for those 0-14 and 15-39 years.

Results: Among 10 107 CNS tumor patients, we found significantly higher odds of regional/distant versus in situ/localized stage diagnoses for those with other discontinuous (OR0-14 = 1.50, 95% CI: 1.15-1.95) and at diagnosis (OR15-39 = 1.41, 95% CI: 1.11-1.78) Medicaid enrollment versus those not enrolled. Those enrolled versus not enrolled in Medicaid had a higher hazard of CNS tumor death for both age groups (HR0-14 = 1.60 95% CI: 1.37-1.86; HR15-39 = 1.50, 95% CI: 1.39-1.62) with the highest hazards for those enrolled at diagnosis (HR0-14 = 1.83, 95% CI: 1.51-2.22; HR15-39 = 1.93, 95% CI: 1.77-2.10).

Conclusions: Medicaid enrollment is associated with a higher risk of CNS tumor death with an almost 2-fold higher risk for young CNS tumor patients enrolled at diagnosis. These results support the critical need for consistent health insurance coverage for young CNS tumor patients.

儿童、青少年和年轻人中中枢神经系统肿瘤诊断阶段和生存与医疗补助登记的关系。
背景:医疗补助登记与年轻癌症患者存活率的差异有关。为了进一步了解中枢神经系统(CNS)肿瘤患者的这种关联,我们使用监测、流行病学和最终结果(SEER)-医疗补助相关数据来检查医疗补助登记与登记时间、(1)诊断阶段和(2)中枢神经系统肿瘤死亡之间的关系。方法:纳入2006年至2013年0至39岁之间诊断为首次恶性原发性中枢神经系统肿瘤的个体。医疗补助登记首先被分类为登记和未登记,而登记的人进一步被分类为连续登记、不连续登记(诊断时或其他不连续登记)或其他登记。我们采用按年龄分层的logistic和Cox比例风险回归计算0-14岁和15-39岁人群的校正优势比(ORs)和风险比(hr)。结果:在10107名中枢神经系统肿瘤患者中,我们发现在其他不连续(OR0-14 = 1.50, 95% CI: 1.15-1.95)和诊断时(OR15-39 = 1.41, 95% CI: 1.11-1.78)加入医疗补助计划的患者与未加入医疗补助计划的患者相比,区域/远处阶段诊断的几率明显高于原位/局部阶段诊断的几率。在两个年龄组中,参加医疗补助计划的患者与未参加医疗补助计划的患者相比,中枢神经系统肿瘤死亡的风险更高(HR0-14 = 1.60, 95% CI: 1.37-1.86;HR15-39 = 1.50, 95% CI: 1.39-1.62),诊断时入组的风险最高(HR0-14 = 1.83, 95% CI: 1.51-2.22;Hr15-39 = 1.93, 95% ci: 1.77-2.10)。结论:加入医疗补助计划与较高的中枢神经系统肿瘤死亡风险相关,诊断时加入的年轻中枢神经系统肿瘤患者的死亡风险几乎高出2倍。这些结果支持了对年轻中枢神经系统肿瘤患者持续健康保险覆盖的迫切需要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neuro-oncology practice
Neuro-oncology practice CLINICAL NEUROLOGY-
CiteScore
5.30
自引率
11.10%
发文量
92
期刊介绍: Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信